Anavex Life Sciences Corp (AVXL)

[Doc328]

Biogen already has their sales reps, managers, medical science liaisons, infusion experts, reimbursement people, etc hired in order to launch within days of the expected approval in March. Approval will be great for BIIB and good for AVXL. A273 is still minimum of 4 years away for AD so this is also a positive for mild AD patients. If A273 works better, it will eventually outperform Aduca in the marketplace just like the oral MS agents are now used more than the older injectable medications.

Nov 6 will be an interesting day. BIIB will get discussed much more but AVXL gets to present on a big Alzheimer day, so will have a chance to shine